Drug Trial Radar · NCT02964013
Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)
Last checked: Nov 19, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
474
Actual
Start
Dec 13, 2016
Primary completion
Jul 24, 2024
Study completion Jul 24, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a safety, efficacy, and pharmacokinetics (PK) study of vibostolimab (MK-7684) as monotherapy and in combination with pembrolizumab (MK-3475) or pembrolizumab plus pemetrexed and carboplatin in adults with metastatic solid tumors for which there is no available therapy that is expected to convey clinical benefit. Part A of this study is a dose escalation and confirmation phase to estimate the recommended Phase 2 dose (RPTD) for vibostolimab monotherapy or in combination with pembrolizumab, pemetrexed, and carboplatin. Part A will also evaluate the anti-tumor activity of vibostolimab in combination with pembrolizumab plus pemetrexed and carboplatin in participants with non-small cell lung cancer (NSCLC) and vibostolimab (at two dose levels) in combination with pembrolizumab in Japanese participants with gastric cancer. Part B will evaluate the anti-tumor activity of vibostolimab at the RPTD when used as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors in a non-randomized study design. Part B will also evaluate 2 doses of vibostolimab in combination with pembrolizumab in participants with programmed death 1 (PD-1) treatment naïve cancer using a 1:1 randomized study design. Part B is expanded with Amendment 11 to include an additional arm that will compare the safety and PK of a fixed dose of pembrolizumab/vibostolimab coformulation (MK-7684A) to vibostolimab in combination with pembrolizumab administered as separate intravenous infusions. Part A is expanded with Amendment 12 to include an additional arm that will compare the safety and PK of vibostolimab plus pembrolizumab plus the investigator's choice of platinum agent (carboplatin or cisplatin), and etoposide. Part B is expanded with Amendment 12 to include evaluation of efficacy of vibostolimab plus pembrolizumab plus the investigator's choice of platinum agent (carboplatin or cisplatin), and etoposide and efficacy of pembrolizumab/vibostolimab coformulation in participants from mainland China. The primary hypotheses are that vibostolimab administered as monotherapy or in combination with pembrolizumab is safe and tolerable when administered at the RPTD and that pembrolizumab/vibostolimab coformulation is safe and tolerable when administered as a fixed dose.
Conditions
- Neoplasms
Interventions
vibostolimabBiological
Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35
pembrolizumabBiological
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
pemetrexedDrug
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
carboplatinDrug
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
pembrolizumab/vibostolimab coformulationBiological
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
cisplatinDrug
Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
etoposideDrug
Administered as an IV infusion on Days 1-3 of 21-day infusion Cycles 1-4
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicities (DLTs) up to 24 MonthsTime frame: Up to 24 Months
- Number of Participants Who Experienced At Least One Adverse Event (AE)Time frame: Up to 28 Months
- Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to 24 Months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.